What’s the current market cap for Personalis stock?

Personalis (PSNL) has a market cap of $1bn as of June 15, 2026.

What is the P/E ratio for Personalis stock?

The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of June 15, 2026.

Does Personalis stock pay dividends?

No, Personalis (PSNL) stock does not pay dividends to its shareholders as of June 15, 2026.

When is the next Personalis dividend payment date?

Personalis (PSNL) stock does not pay dividends to its shareholders.

What is the beta indicator for Personalis?

Personalis (PSNL) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Personalis stock | $PSNL Share Price

13:30

15:10

16:45

18:25

20:00

About Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Ticker

$PSNL

Sector

Health

Primary listing

NASDAQ

Employees

260

Headquarters

Fremont, United States

Website

www.personalis.com

Personalis Metrics

BasicAdvanced

$1bn

-$1.02

1.97

What the Analysts think about Personalis

Analyst ratings (Buy, Hold, Sell) for Personalis stock.

Bulls say / Bears say

Clinical test volume surged 41% sequentially to 6,183 tests in Q4 2025, driving full-year volume of 16,233 tests and exceeding initial 2025 projections. (Seeking Alpha)

Personalis received Medicare coverage for its NeXT Personal ultrasensitive MRD test for post-treatment surveillance of breast cancer recurrence, effective retroactively October 7, 2025, validating reimbursement under CMS. (Investing.com)

The company ended Q4 2025 with approximately $240 million in cash and short-term investments and minimal debt, providing a multi-year runway to execute its MRD-focused growth strategy. (MarketBeat)

Total revenue in Q1 2026 declined 25% year-over-year to $15.5 million, reflecting contraction in pharma testing, enterprise sales, and population sequencing segments. (MarketBeat)

Net loss widened to $30 million in Q1 2026, driven by elevated operating expenses and scaling costs for clinical diagnostic and R&D initiatives, highlighting a prolonged path to profitability. (MarketBeat)

Personalis faces significant customer concentration, with a limited number of large contracts—such as Natera, the VA MVP, and Merck—accounting for a substantial portion of revenue and posing volatility risk should partnerships change. (Seeking Alpha)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

Personalis Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Personalis Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PSNL

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Clinical test volume surged 41% sequentially to 6,183 tests in Q4 2025, driving full-year volume of 16,233 tests and exceeding initial 2025 projections. (Seeking Alpha)

The company ended Q4 2025 with approximately $240 million in cash and short-term investments and minimal debt, providing a multi-year runway to execute its MRD-focused growth strategy. (MarketBeat)

Total revenue in Q1 2026 declined 25% year-over-year to $15.5 million, reflecting contraction in pharma testing, enterprise sales, and population sequencing segments. (MarketBeat)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.